Platelet-Mediated Mesenchymal Stem Cells Homing to the Lung Reduces Monocrotaline-Induced Rat Pulmonary Hypertension
Bone marrow mesenchymal stem cell (BM-MSC) transplantation has been suggested to be a promising method for the treatment of pulmonary arterial hypertension (PAH), a fatal disease currently without effective preventive/therapeutic strategies. However, the detailed mechanisms underlying BM-MSC therapy...
Main Authors: | Lei Jiang, Xing Hui Song, Pu Liu, Chun Lai Zeng, Zhang Sen Huang, Lin Jing Zhu, Yang Zi Jiang, Hong Wei Ouyang, Hu Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-07-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.3727/096368912X640529 |
Similar Items
-
Polydatin Glycosides Improve Monocrotaline-Induced Pulmonary Hypertension Injury by Inhibiting Endothelial-To-Mesenchymal Transition
by: Xing Chen, et al.
Published: (2022-03-01) -
Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition
by: Yonghui Wu, et al.
Published: (2021-07-01) -
The protective role of EP300 in monocrotaline-induced pulmonary hypertension
by: Lei Yang, et al.
Published: (2023-02-01) -
Effects of alamandine on monocrotaline-induced pulmonary hypertension in rats
by: Ava Soltani Hekmat, et al.
Published: (2024-04-01) -
Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats
by: Igor Bastos Polonio, et al.
Published: (2014-08-01)